Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particles.
Adult
Calcium
/ blood
Cross-Sectional Studies
Diabetes Mellitus
Female
Glomerular Filtration Rate
Humans
Hydrodynamics
Light
Male
Middle Aged
Odds Ratio
Phosphates
/ blood
Photometry
/ methods
Regression Analysis
Renal Insufficiency, Chronic
/ blood
Scattering, Radiation
Vascular Calcification
/ blood
Young Adult
calcification propensity
calciprotein particle
chronic kidney disease
mineral metabolism
vascular calcification
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
16
02
2018
pubmed:
23
5
2018
medline:
15
4
2020
entrez:
23
5
2018
Statut:
ppublish
Résumé
The size of secondary calciprotein particles (CPP2) and the speed of transformation (T50) from primary calciprotein particles (CPP1) to CPP2 in serum may be associated with vascular calcification (VC) in patients with chronic kidney disease (CKD). We developed a high throughput, microplate-based assay using dynamic light scattering (DLS) to measure the transformation of CPP1 to CPP2, hydrodynamic radius (Rh) of CPP1 and CPP2, T50 and aggregation of CPP2. We used this DLS assay to test the hypothesis that a large Rh of CPP2 and/or a fast T50 are associated with VC in 45 participants with CKD Stages 4-5 (22 without VC and 23 with VC) and 17 healthy volunteers (HV). VC was defined as a Kauppila score >6 or an Adragao score ≥3. CKD participants with VC had larger cumulants Rh of CPP2 {370 nm [interquartile range (IQR) 272-566]} compared with CKD participants without VC [212 nm (IQR 169-315)] and compared with HV [168 nm (IQR 145-352), P < 0.01 for each]. More CPP2 were in aggregates in CKD participants with VC than those without VC (70% versus 36%). The odds of having VC increased by 9% with every 10 nm increase in the Rh of CPP2, after adjusting for age, diabetes, serum calcium and phosphate [odds ratio 1.09, 95% confidence interval (CI) 1.03, 1.16, P = 0.005]. The area under the receiver operating characteristic curve for VC of CPP2 size was 0.75 (95% CI 0.60, 0.90). T50 was similar in CKD participants with and without VC, although both groups had a lower T50 than HV. Rh of CPP2, but not T50, is independently associated with VC in patients with CKD Stages 4-5.
Sections du résumé
BACKGROUND
The size of secondary calciprotein particles (CPP2) and the speed of transformation (T50) from primary calciprotein particles (CPP1) to CPP2 in serum may be associated with vascular calcification (VC) in patients with chronic kidney disease (CKD).
METHODS
We developed a high throughput, microplate-based assay using dynamic light scattering (DLS) to measure the transformation of CPP1 to CPP2, hydrodynamic radius (Rh) of CPP1 and CPP2, T50 and aggregation of CPP2. We used this DLS assay to test the hypothesis that a large Rh of CPP2 and/or a fast T50 are associated with VC in 45 participants with CKD Stages 4-5 (22 without VC and 23 with VC) and 17 healthy volunteers (HV). VC was defined as a Kauppila score >6 or an Adragao score ≥3.
RESULTS
CKD participants with VC had larger cumulants Rh of CPP2 {370 nm [interquartile range (IQR) 272-566]} compared with CKD participants without VC [212 nm (IQR 169-315)] and compared with HV [168 nm (IQR 145-352), P < 0.01 for each]. More CPP2 were in aggregates in CKD participants with VC than those without VC (70% versus 36%). The odds of having VC increased by 9% with every 10 nm increase in the Rh of CPP2, after adjusting for age, diabetes, serum calcium and phosphate [odds ratio 1.09, 95% confidence interval (CI) 1.03, 1.16, P = 0.005]. The area under the receiver operating characteristic curve for VC of CPP2 size was 0.75 (95% CI 0.60, 0.90). T50 was similar in CKD participants with and without VC, although both groups had a lower T50 than HV.
CONCLUSIONS
Rh of CPP2, but not T50, is independently associated with VC in patients with CKD Stages 4-5.
Identifiants
pubmed: 29788425
pii: 4996711
doi: 10.1093/ndt/gfy117
pmc: PMC6545469
doi:
Substances chimiques
Phosphates
0
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
992-1000Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001999
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK075462
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR026501
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR027241
Pays : United States
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Références
Kidney Int Suppl (2011). 2013 Dec;3(5):442-445
pubmed: 25019027
Nephrol Dial Transplant. 2012 May;27(5):1957-66
pubmed: 22105144
Nephrol Dial Transplant. 2003 Sep;18(9):1731-40
pubmed: 12937218
J Am Chem Soc. 2010 Feb 24;132(7):2163-5
pubmed: 20112897
Circulation. 1999 May 11;99(18):2434-9
pubmed: 10318666
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):315-322
pubmed: 27940458
J Biol Chem. 2008 May 23;283(21):14815-25
pubmed: 18364352
Biochem J. 1990 Mar 15;266(3):863-8
pubmed: 2158302
Clin J Am Soc Nephrol. 2015 Apr 7;10(4):654-66
pubmed: 25770175
J Biol Chem. 1996 Aug 23;271(34):20789-96
pubmed: 8702833
Circulation. 2001 Mar 20;103(11):1529-34
pubmed: 11257080
Nephrol Dial Transplant. 2008 Dec;23(12):4009-15
pubmed: 18676346
Sci Rep. 2017 Jul 18;7(1):5686
pubmed: 28720774
PLoS One. 2009;4(5):e5421
pubmed: 19412552
J Biol Chem. 2003 Apr 11;278(15):13333-41
pubmed: 12556469
Sci Rep. 2018 Jan 19;8(1):1256
pubmed: 29352150
Clin J Am Soc Nephrol. 2009 Dec;4(12):1883-5
pubmed: 19965543
Nephrol Dial Transplant. 2004 Jun;19(6):1480-8
pubmed: 15034154
Stroke. 2001 Feb;32(2):454-60
pubmed: 11157182
Circ Res. 2012 Aug 17;111(5):575-84
pubmed: 22753077
J Am Soc Nephrol. 2014 Feb;25(2):339-48
pubmed: 24179171
Hypertension. 1998 Sep;32(3):570-4
pubmed: 9740628
Clin J Am Soc Nephrol. 2011 Feb;6(2):303-10
pubmed: 20930091
Trends Cardiovasc Med. 2007 May;17(4):124-8
pubmed: 17482094
J Clin Invest. 2003 Aug;112(3):357-66
pubmed: 12897203
Curr Opin Nephrol Hypertens. 2016 Jul;25(4):278-84
pubmed: 27228365
J Am Soc Nephrol. 2010 Nov;21(11):1998-2007
pubmed: 20947626
Biomacromolecules. 2010 Nov 8;11(11):2836-9
pubmed: 20961117
J Am Soc Nephrol. 2009 Jun;20(6):1264-74
pubmed: 19389852
Atherosclerosis. 1997 Jul 25;132(2):245-50
pubmed: 9242971
J Am Soc Nephrol. 2012 Oct;23(10):1744-52
pubmed: 22956818